RECRUITING

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.

Official Title

A Pilot Study of Using [18F]F AraG PET Imaging to Evaluate the Immunological Response to Checkpoint Inhibitor Therapy (CkIT) in Patients With Advanced Solid Tumors

Quick Facts

Study Start:2022-03-01
Study Completion:2026-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04260256

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Solid tumor with planned CkIT
  2. * Must be \>18 years old
  3. * Signed Informed Consent Form
  4. * Patient must have two qualifying lesions
  1. * Patient is pregnant or breast feeding

Contacts and Locations

Study Contact

LIbby Mirande
CONTACT
503 494 4740
jenselib@ohsu.edu

Principal Investigator

Carina Mari Aparici, M.D.
PRINCIPAL_INVESTIGATOR
Stanford University
Erik Mittra, M.D.
PRINCIPAL_INVESTIGATOR
Oregon Health and Science University
Shivaani Kummar, M.D.
PRINCIPAL_INVESTIGATOR
Oregon Health and Science University

Study Locations (Sites)

Stanford University
Stanford, California, 94305
United States
Oregon Health and Science University
Portland, Oregon, 97239
United States

Collaborators and Investigators

Sponsor: CellSight Technologies, Inc.

  • Carina Mari Aparici, M.D., PRINCIPAL_INVESTIGATOR, Stanford University
  • Erik Mittra, M.D., PRINCIPAL_INVESTIGATOR, Oregon Health and Science University
  • Shivaani Kummar, M.D., PRINCIPAL_INVESTIGATOR, Oregon Health and Science University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-03-01
Study Completion Date2026-11-30

Study Record Updates

Study Start Date2022-03-01
Study Completion Date2026-11-30

Terms related to this study

Additional Relevant MeSH Terms

  • Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit